Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Brexit

Pharma Retains Brexit Premium Skepticism

Scrip and IQVia explore how Brexit will impact clinical trials, product launches and funding in the UK.

Brexit Business Strategies Clinical Trials

Quality UK Biotechs Will Dodge Post-Brexit VC Drought

With the UK deadline to leave the European Union just over 12 months away, UK companies will see access to European Investment Fund-backed venture capital restricted. Quality companies, however, should not be fearful.

Commercial Companies Financing

Latest From Brexit

Ipsen CEO: 'I Assume a Hard Brexit', But Remain Bullish On UK Life Sciences

Ipsen's David Meek tells Scrip a Hard Brexit looks likely and that he's preparing the French pharma for that scenario.

Brexit Business Strategies

BIO Notebook Day 4: Gottlieb Seeks Early Engagement On Gene Therapy; Ireland’s Brexit Opportunities; AMAG’s Bremelanotide Strategy; Alzheimer’s ‘Learnings’

US FDA to head off cell/gene therapy manufacturing issues with pre-IND meetings; Republic of Ireland will “chase any opportunities” for business partners stemming from Brexit, even while hoping UK reconsiders EU departure; AMAG won’t follow the flibanserin PR approach with newly submitted female sexual dysfunction drug bremelanotide; United Neuroscience CMO Ajay Verma says Alzheimer’s trial setbacks are “learnings,” with progress toward novel therapies moving faster than it has for cancer and HIV.

Regenerative Medicine Neurology

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Brexit Market Access

2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

Brexit Commercial

What Does 2018 Hold For Biopharma?

From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics. Here is our digest.

Commercial Strategy

UK Life Science 'Needs Manufacturing Incentives, NHS Access' After Brexit

MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.

Brexit Business Strategies
See All